NASDAQ:GLYC - Nasdaq - US38000Q1022 - Common Stock - Currency: USD
0.223
+0 (+0.45%)
The current stock price of GLYC is 0.223 USD. In the past month the price decreased by -17.83%. In the past year, price decreased by -88.42%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.09 | 306.02B | ||
AMGN | AMGEN INC | 13.99 | 149.08B | ||
GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
ARGX | ARGENX SE - ADR | 320.54 | 36.40B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
ONC | BEIGENE LTD-ADR | N/A | 24.89B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
NTRA | NATERA INC | N/A | 20.02B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
BIIB | BIOGEN INC | 7.2 | 17.36B |
GlycoMimetics, Inc. is a biotechnology company, which engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2014-01-10. The firm has no ongoing operations, is not performing any research and development, and is preserving cash until the contemplated merger and private placement. The firm was developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates such as the roles they play in cancers and inflammation.
GLYCOMIMETICS INC
9708 Medical Center Drive
Rockville MARYLAND 20850 US
CEO: Rachel K. King
Employees: 35
Company Website: https://glycomimetics.com/
Investor Relations: http://ir.glycomimetics.com/
Phone: 12402431201
The current stock price of GLYC is 0.223 USD. The price increased by 0.45% in the last trading session.
The exchange symbol of GLYCOMIMETICS INC is GLYC and it is listed on the Nasdaq exchange.
GLYC stock is listed on the Nasdaq exchange.
7 analysts have analysed GLYC and the average price target is 1.02 USD. This implies a price increase of 357.4% is expected in the next year compared to the current price of 0.223. Check the GLYCOMIMETICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GLYCOMIMETICS INC (GLYC) has a market capitalization of 14.39M USD. This makes GLYC a Nano Cap stock.
GLYCOMIMETICS INC (GLYC) currently has 35 employees.
GLYCOMIMETICS INC (GLYC) has a support level at 0.18 and a resistance level at 0.23. Check the full technical report for a detailed analysis of GLYC support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GLYC does not pay a dividend.
GLYCOMIMETICS INC (GLYC) will report earnings on 2025-05-07.
GLYCOMIMETICS INC (GLYC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.59).
The outstanding short interest for GLYCOMIMETICS INC (GLYC) is 4.57% of its float. Check the ownership tab for more information on the GLYC short interest.
ChartMill assigns a fundamental rating of 2 / 10 to GLYC. The financial health of GLYC is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months GLYC reported a non-GAAP Earnings per Share(EPS) of -0.59. The EPS decreased by -1.14% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -341.52% | ||
ROE | -712.87% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 86% to GLYC. The Buy consensus is the average rating of analysts ratings from 7 analysts.